Please login to the form below
Oseni
This page shows the latest Oseni news and features for those working in and with pharma, biotech and healthcare.
Forest Labs agrees $1.46bn deal to buy Furiex
Furiex also has a stable of marketed drugs for diabetes including Nesina (alogliptin) and fixed-dose combination therapies Oseni/Liovel (alogliptin/pioglitazone) and Kazan (alogliptin/metformin), which are sold by Takeda,
Latest news
-
FDA investigates pancreas risk of diabetes drugs
Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.
-
Takeda gets FDA approval for alogliptin franchise in diabetes
Comprises Nesina, Oseni and Kazano. Takeda was celebrating at the end of last week after the FDA granted approval to three of its diabetes drug candidates. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Sinovac reveals positive preliminary data for COVID-19 vaccine
- Finalists 2020 - Communiqué Awards
- Novartis pulls EU filing for $3.4bn eye therapy Xiidra
- Novo Nordisk gets another OK for oral GLP-1 drug Rybelsus
- Remdesivir closes in on receiving first EU approval for treatment for COVID-19
- Syneos Health appoints trio of senior hires
- Syneos Health appoints Tim Pantello as president of communications
- The best work in healthcare communications shines at virtual Communiqué Awards
- Mearns & Pike, Electric Putty and Evoke KYNE make a clean sweep at Communiqué 2020
- 90TEN scoops Communiqué Communications Consultancy of the Year Award for the Second Year Running
- NHS test and trace system ‘still not good enough’ says health leader
PMHub
infill healthcare communication
infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...
Latest intelligence
- The search for treatments for Parkinson’s disease
- The research requires resilience but pharma is urged to ‘keep innovating, keep trying’...
- Margot Hannah, OPEN Health - A personal perspective of LGBT+ and diversity.
- Ditch the Label – it’s just me....
- The impact of COVID-19 on clinical trials
- As all industry sectors work to assess both the impact and the optimal path forward, the effects are expected to be diverse and long-lasting...
Quick links
Infographics
